SynthesisInfectious disorders drug targets2025
Antimicrobial Resistance of Environmental
Synthesis in Infectious disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe understanding of the antibiotic resistance status of environmental nonO1/nonO139 V. cholerae (NOVC) in relation to other illnesses, which can vary in severity from mild to life-threatening, is limited. However, it is important to note that NOVC-related infections are increasing and serve as a significant illustration of emerging human diseases associated with climate change. The primary objective of the present study was to assess the rates of resistance observed in environmental NOVC isolates across various years, and regions, and their resistance rates.
methodsWe performed a systematic search of Scopus, PubMed, Web of Science, and EMBASE databases (until May 2024) following PRISMA guidelines. All statistical analyses were carried out using the statistical package R.
resultsOur analysis included a total of 34 studies. According to the meta-regression, chloramphenicol, rifampicin, ciprofloxacin, nalidixic acid, cotrimoxazole, kanamycin, trimethoprim, amoxicillin/clavulanic acid, and tetracycline resistance rate increased over time. The lowest resistance rates were observed in Austria (amoxicillin; 0.6%), the United States (kanamycin; 0.1% and tetracycline; 0.1%), Morocco (polymyxin B; 12%), and Spain (trimethoprim; 0.3%). Conversely, the highest resistance rates were found in Spain (amoxicillin; 61%), Indonesia (kanamycin and tetracycline; 94.9%), India (polymyxin B; 97.8%), and Morocco (trimethoprim; 48.9%).
conclusionThe meta-analysis showed significant variability in antibiotic resistance patterns among environmental NOVC isolates across time and regions, emphasizing the need for targeted, time-specific, and country-specific approaches to address antibiotic resistance globally.
Indexed as
Identifiers
39440733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.